CURRICULUM VITAE:

PROF. Dr. med. Martin Reck (MD PhD)

Head of Department of Thoracic Oncology Head of Department of Clinical Trials LungenClinic Grosshansdorf Woehrendamm 80 22927 Großhansdorf Germany

Date of birth: 17.07.1965

Scientific and professional career:

Since 2016	Professor, Department of Internal Medicine, University of Lübeck, Germany
Since 2011	Head of Department of Thoracic Oncology, LungenClinic Grosshansdorf
Since 2003	Assistant Medical Director, LungenClinic Grosshansdorf Head of Department of Clinical Trials
2008	Habilitation, university of Lübeck, Germany
	Topic of thesis: New approaches in systemic treatment of NSCLC and SCLC
2002	Board Certification Respiratory Medicine
2001	Board Certification Internal Medicine
2000 - 2002	Training Respiratory Medicine, LungenClinic Grosshansdorf
1997 – 2000	Training Internal Medicine, General Hospital Wandsbek, Hamburg, Germany
1995 - 1997	Training Internal Medicine, LungenClinic Grosshansdorf, Germany
1995	Doctorate, university of Hamburg, Germany
	Topic of thesis: Chemotherapy of SCLC with Carboplatin, Etoposide and Vincristine
1995	Full Medical Licence, Medical Association Schleswig Holstein, Germany
1993 - 1995	Medical Training, LungenClinic Grosshansdorf, Germany
1993	Medical licence, medical school of Hamburg, Germany
1986 - 1993	Training, medical school of Hamburg, Germany

Clinical Responsibilities (since 2003):

- All diagnostic and functional assessments for patients with thoracic malignancies
- Interventional endobronchial operations and stent applications
- Planning and supervision of chemotherapies and targeted therapies in patients with thoracic malignancies
- PI, national coordinating PI (LKP) and global coordinating PI (CI) in phase I-III trials in patients with NSCLC, SCLC and pleural mesothelioma

Scientific Responsibilities:

```
Since 2010
```

•

٠

Principle Investigator (PI) of the Airway Research Centre North (ARCN) within the Government funded German Centre for lung research (DZL) in area of Lung Cancer. Current projects:

- Malignant transition of lung tissue
- Determination of gene expression profiles and pathways associated with malignant transition
- Patterns of resistance following chemoradiotherapy in locally advanced NSCLC
- Patterns of resistance following systemic chemotherapy and targeted therapies

Memberships / Academic responsibilities:

- European Society of Medical Oncology (ESMO)
 - Member Faculty Committee Chest
 - Member Guidelines Working Group, Deputy Chest Tumors
 - Member Fellowship and Award Committee
 - Scientific Committee EMCTO 2012, ELCC 2012-2019, ESMO 2013-2018
 - European Thoracic Oncology Platform (ETOP)
 - Associated Editor ETOP Website Rare Tumours, pleural mesothelioma
- EORTC Lung Group (chair subcommittee NSCLC metastatic)
- American Society of Oncology (ASCO)
- International Association for the study of lung cancer (IASLC)
 - Chair Membership Committee 2009-2011
 - o Scientific Committee WCLC 2015, 2016
 - \circ Member Board of Directors
- German Cancer Society (DKG)
- German Working Group for Oncology (AIO)
 - Board Member
- German society for internal medicine (DGIM)
- German society for respiratory medicine (DGP)
 - Chair section Thoracic Oncology (2007-2012)
 - Northern Working Group on Lung Cancer (NBA)
 - \circ Chair